Cargando…

Combination therapies enhance immunoregulatory properties of MIAMI cells

BACKGROUND: Mesenchymal stromal cells (MSCs), adult stromal cells most commonly isolated from bone marrow (BM), are being increasingly utilized in various therapeutic applications including tissue repair via immunomodulation, which is recognized as one of their most relevant mechanism of action. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Fiorella, Noren, Hunter, Sarria, Leonor, Schiller, Paul C., Nathanson, Lubov, Beljanski, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921447/
https://www.ncbi.nlm.nih.gov/pubmed/31852519
http://dx.doi.org/10.1186/s13287-019-1515-3
_version_ 1783481164353241088
author Rossi, Fiorella
Noren, Hunter
Sarria, Leonor
Schiller, Paul C.
Nathanson, Lubov
Beljanski, Vladimir
author_facet Rossi, Fiorella
Noren, Hunter
Sarria, Leonor
Schiller, Paul C.
Nathanson, Lubov
Beljanski, Vladimir
author_sort Rossi, Fiorella
collection PubMed
description BACKGROUND: Mesenchymal stromal cells (MSCs), adult stromal cells most commonly isolated from bone marrow (BM), are being increasingly utilized in various therapeutic applications including tissue repair via immunomodulation, which is recognized as one of their most relevant mechanism of action. The promise of MSC-based therapies is somewhat hindered by their apparent modest clinical benefits, highlighting the need for approaches that would increase the efficacy of such therapies. Manipulation of cellular stress-response mechanism(s) such as autophagy, a catabolic stress-response mechanism, with small molecules prior to or during MSC injection could improve MSCs’ therapeutic efficacy. Unfortunately, limited information exists on how manipulation of autophagy affects MSCs’ response to inflammation and subsequent immunoregulatory properties. METHODS: In this study, we exposed BM-MSC precursor cells, “marrow-isolated adult multilineage inducible” (MIAMI) cells, to autophagy modulators tamoxifen (TX) or chloroquine (CQ), together with IFN-γ. Exposed cells then underwent RNA sequencing (RNAseq) to determine the effects of TX or CQ co-treatments on cellular response to IFN-γ at a molecular level. Furthermore, we evaluated their immunoregulatory capacity using activated CD4+ T cells by analyzing T cell activation marker CD25 and the percentage of proliferating T cells after co-culturing the cells with MIAMI cells treated or not with TX or CQ. RESULTS: RNAseq data indicate that the co-treatments alter both mRNA and protein levels of key genes responsible for MSCs’ immune-regulatory properties. Interestingly, TX and CQ also altered some of the microRNAs targeting such key genes. In addition, while IFN-γ treatment alone increased the surface expression of PD-L1 and secretion of IDO, this increase was further enhanced with TX. An improvement in MIAMI cells’ ability to decrease the activation and proliferation of T cells was also observed with TX, and to a lesser extent, CQ co-treatments. CONCLUSION: Altogether, this work suggests that both TX and CQ have a potential to enhance MIAMI cells’ immunoregulatory properties. However, this enhancement is more pronounced with TX co-treatment.
format Online
Article
Text
id pubmed-6921447
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69214472019-12-30 Combination therapies enhance immunoregulatory properties of MIAMI cells Rossi, Fiorella Noren, Hunter Sarria, Leonor Schiller, Paul C. Nathanson, Lubov Beljanski, Vladimir Stem Cell Res Ther Research BACKGROUND: Mesenchymal stromal cells (MSCs), adult stromal cells most commonly isolated from bone marrow (BM), are being increasingly utilized in various therapeutic applications including tissue repair via immunomodulation, which is recognized as one of their most relevant mechanism of action. The promise of MSC-based therapies is somewhat hindered by their apparent modest clinical benefits, highlighting the need for approaches that would increase the efficacy of such therapies. Manipulation of cellular stress-response mechanism(s) such as autophagy, a catabolic stress-response mechanism, with small molecules prior to or during MSC injection could improve MSCs’ therapeutic efficacy. Unfortunately, limited information exists on how manipulation of autophagy affects MSCs’ response to inflammation and subsequent immunoregulatory properties. METHODS: In this study, we exposed BM-MSC precursor cells, “marrow-isolated adult multilineage inducible” (MIAMI) cells, to autophagy modulators tamoxifen (TX) or chloroquine (CQ), together with IFN-γ. Exposed cells then underwent RNA sequencing (RNAseq) to determine the effects of TX or CQ co-treatments on cellular response to IFN-γ at a molecular level. Furthermore, we evaluated their immunoregulatory capacity using activated CD4+ T cells by analyzing T cell activation marker CD25 and the percentage of proliferating T cells after co-culturing the cells with MIAMI cells treated or not with TX or CQ. RESULTS: RNAseq data indicate that the co-treatments alter both mRNA and protein levels of key genes responsible for MSCs’ immune-regulatory properties. Interestingly, TX and CQ also altered some of the microRNAs targeting such key genes. In addition, while IFN-γ treatment alone increased the surface expression of PD-L1 and secretion of IDO, this increase was further enhanced with TX. An improvement in MIAMI cells’ ability to decrease the activation and proliferation of T cells was also observed with TX, and to a lesser extent, CQ co-treatments. CONCLUSION: Altogether, this work suggests that both TX and CQ have a potential to enhance MIAMI cells’ immunoregulatory properties. However, this enhancement is more pronounced with TX co-treatment. BioMed Central 2019-12-18 /pmc/articles/PMC6921447/ /pubmed/31852519 http://dx.doi.org/10.1186/s13287-019-1515-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Rossi, Fiorella
Noren, Hunter
Sarria, Leonor
Schiller, Paul C.
Nathanson, Lubov
Beljanski, Vladimir
Combination therapies enhance immunoregulatory properties of MIAMI cells
title Combination therapies enhance immunoregulatory properties of MIAMI cells
title_full Combination therapies enhance immunoregulatory properties of MIAMI cells
title_fullStr Combination therapies enhance immunoregulatory properties of MIAMI cells
title_full_unstemmed Combination therapies enhance immunoregulatory properties of MIAMI cells
title_short Combination therapies enhance immunoregulatory properties of MIAMI cells
title_sort combination therapies enhance immunoregulatory properties of miami cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921447/
https://www.ncbi.nlm.nih.gov/pubmed/31852519
http://dx.doi.org/10.1186/s13287-019-1515-3
work_keys_str_mv AT rossifiorella combinationtherapiesenhanceimmunoregulatorypropertiesofmiamicells
AT norenhunter combinationtherapiesenhanceimmunoregulatorypropertiesofmiamicells
AT sarrialeonor combinationtherapiesenhanceimmunoregulatorypropertiesofmiamicells
AT schillerpaulc combinationtherapiesenhanceimmunoregulatorypropertiesofmiamicells
AT nathansonlubov combinationtherapiesenhanceimmunoregulatorypropertiesofmiamicells
AT beljanskivladimir combinationtherapiesenhanceimmunoregulatorypropertiesofmiamicells